The application requests continued support of the Minority Based CCOP at the University of South Alabama. The grant has provided support of the administrative and data management of cancer treatment protocols and cancer control programs at the University of South Alabama where one-half of our patients are from minority populations. Cancer treatment protocols are mostly associated with either the Southwest Oncology Group (SWOG) or the Pediatric Oncology Group (POG). However, we are initiating treatment studies with the National Surgical Adjuvant Breast Program (NSABP) with patients for whom there is not an available protocol. Cancer prevention trials have been undertaken with NSABP, MD Anderson Cancer Center (MSKCC) and we have established affiliation with the University of Rochester for this purpose. We are a participant in the Breast Cancer Prevention Trial (BCPT) and have been accepted as a participant in the Prostate Cancer Prevention Trial (PCPT). A program was established to ascertain reasons for diminished participation of minority groups in cancer prevention and control projects. This is being done with the assistance of the Sickle - Cell Disease Association of the Gulf Coast and the University of South Alabama Comprehensive Sickle Cell Center. Measurements are being made of responses to advertisements and direct mailings in both caucasian and African American populations which have been paired for different socioeconomic levels. Direct surveys are in progress by interview to determine reason for participation or lack of participation in these groups. To date, our data suggests that minority women of an age to be eligible for the BCPT have a distrust of institutions and research and possess a fatalistic attitude regarding cancer prevention and control. The University of South Alabama Medical Center (USAMC) is the only University hospital within a 150 mile radius on the Gulf Coast. It serves southern Alabama, southern Mississippi and the panhandle of Florida. It is the only hospital in the region willing and capable of providing oncologic care for patients regardless of payment capability. Minority populations include African Americans, American Indians and immigrants from Vietnam and Cambodia. The USAMC has 800 beds and 32 beds are in a designated adult oncology unit. Approximately 550 new cancer patients are seen yearly at this facility and subsequently followed in the Cancer Center following discharge. Data from all cancer patients are entered into a patient log and this information is shared with NCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA052654-05
Application #
2094888
Study Section
Special Emphasis Panel (SRC (86))
Project Start
1990-09-14
Project End
1998-05-31
Budget Start
1995-06-01
Budget End
1996-05-31
Support Year
5
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of South Alabama
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Mobile
State
AL
Country
United States
Zip Code
36688
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Malhotra, Binu; Moon, James; Kucuk, Omar et al. (2014) Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 36:1712-7
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70

Showing the most recent 10 out of 97 publications